Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 16;12(1):52.
doi: 10.1186/s13023-017-0598-0.

Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature

Benedikt Schoser  1 , Edward Fong  2 , Tarekegn Geberhiwot  3 , Derralynn Hughes  4 , John T Kissel  5 , Shyam C Madathil  6 , David Orlikowski  7 , Michael I Polkey  8 , Mark Roberts  9 , Harm A W M Tiddens  10 , Peter Young  11
Affiliations
Review

Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature

Benedikt Schoser et al. Orphanet J Rare Dis. .

Abstract

Respiratory muscle strength is a proven predictor of long-term outcome of neuromuscular disease (NMD), including amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and spinal muscular atrophy. Maximal inspiratory pressure (MIP), a sensitive measure of respiratory muscle strength, one of several useful tests of respiratory muscle strength, is gaining interest as a therapeutic clinical trial endpoint for NMD. In this comprehensive review we investigate the use of MIP as a measure of respiratory muscle strength in clinical trials of therapeutics targeting respiratory muscle, examine the correlation of MIP with survival, quality of life, and other measures of pulmonary function, and outline the role of MIP as a clinically significantly meaningful outcome measure. Our analysis supports the utility of MIP for the early evaluation of respiratory muscle strength, especially of the diaphragm, in patients with NMD and as a surrogate endpoint in clinical trials of therapies for NMD.

Keywords: Endpoint; Maximum inspiratory pressure; Neuromuscular disease; Pulmonary function testing; Respiratory failure; Spirometry; Survival.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve. 2004;29:5–27. doi: 10.1002/mus.10487. - DOI - PubMed
    1. Epstein SK. An overview of respiratory muscle function. Clin Chest Med. 1994;15:619–639. - PubMed
    1. Sansone VA, Gagnon C. 207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27–29 June 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25:432–442. doi: 10.1016/j.nmd.2015.01.011. - DOI - PubMed
    1. Ambrosino N, Gherardi M, Carpenè N. End stage chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2009;77:173–179. - PubMed
    1. Farrero E, Antón A, Egea CJ, et al. Guidelines for the management of respiratory complications in patients with neuromuscular disease. Arch Bronconeumol. 2013;49:306–313. doi: 10.1016/j.arbres.2012.12.003. - DOI - PubMed

Publication types

MeSH terms